Key result
Support vector machine model predicts 6-month CMV infection in kidney transplant recipients with ~0.82 AUC.
Observational (n=162)
No
Effect estimate: AUC 0.821 (95% CI 0.692-0.932)
An interpretable SVM model incorporating clinical and immune variables, particularly T-cell subsets, effectively predicts the risk of CMV infection in seropositive kidney transplant recipients.
May refine CMV risk stratification beyond serostatus in R+ recipients; leaves open prospective validation before clinical adoption.
Background: Cytomegalovirus (CMV) infection is a serious complication after kidney transplantation. Although most recipients are CMV-seropositive (R+), preventive strategies for this group remain controversial, whereas they are relatively well established for CMV-seronegative recipients (R–). Conventional serostatus-based classification alone is insufficient to accurately assess infection risk in R+ individuals. Therefore, we aimed to develop machine learning models that integrate clinical and immune variables to provide a precise risk prediction tool for CMV infection in R+ recipients. Methods: This study included patients from June 2023 to December 2024, and were randomly divided into training and validation cohorts in a 7:3 ratio. Feature selection was performed in the training cohort using the Boruta algorithm. Six machine learning models were applied to identify the best model for predicting CMV infection risk in R+ patients, and model interpretability was assessed using SHAP. Results: Of 162 R+ patients, 51.2% developed CMV DNAemia. Seven key predictors were identified, including T-cell subsets (CD8+, CD4+, CD4+CD27−), recipient age, cold ischemia time, donor type, and prevention strategy. Among these, CD4+ and CD8+ T-cell subset counts were the most influential predictors, with lower counts associated with a higher risk of CMV infection. The support vector machine (SVM) achieved the best discrimination in the validation cohort (AUC, 0.821; 95% CI, 0.692– 0.932). Conclusion: The interpretable SVM model showed promising performance for identifying R+ recipients at high risk of CMV infection and potentially individualized prophylactic and monitoring strategies. External validation in prospective cohorts is warranted.
No takes yet. Share an insight, caveat, or question.
Zhong et al. (2026) conducted an observational in Cytomegalovirus (CMV) infection in seropositive kidney transplant recipients (n=162). Support vector machine (SVM) predictive model was evaluated on Prediction of CMV DNAemia within 6 months (AUC) (AUC 0.821, 95% CI 0.692-0.932). An interpretable support vector machine model predicted cytomegalovirus infection within 6 months in seropositive kidney transplant recipients with an AUC of 0.821.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: